Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 112 publications
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma.
Journal: The Journal of clinical investigation
Published: February 12, 2026
Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma.
Journal: Journal of experimental & clinical cancer research : CR
Published: January 28, 2026
Current treatment strategies for first relapse of high-risk neuroblastoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 16, 2025
IDH1 R132 mutations or HER2-positivity and benefit from platinum-based therapy for biliary tract cancers.
Journal: JHEP reports : innovation in hepatology
Published: December 13, 2025
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 12, 2025
The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers.
Journal: Cancer research
Published: November 19, 2025
Differential chromatin accessibility response to retinoic acid in neuroblastoma with ATRX in-frame-deletions versus ATRX loss-of-function.
Journal: Neoplasia (New York, N.Y.)
Published: August 06, 2025
Anti-Tumor Activity of Cdk2/9 Inhibitor Fadraciclib in an In Vivo Model of Temozolomide Refractory Neuroblastoma.
Journal: Molecular cancer therapeutics
Published: July 26, 2025
MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition.
Journal: Cell reports
Published: June 25, 2025
MIF-CD74 signaling drives immune modulation in medulloblastoma.
Journal: Neuro-oncology
Published: June 13, 2025
Last Updated: 09/26/2026